Short answer
Liquidia Corp (LQDA) filed an 8-K current report with the SEC on August 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.2). Filing contains only signature certification, dated August 12, 2026.
Liquidia Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Filing contains only signature certification, dated August 12, 2026
- No earnings figures, reporting-period results, or operating metrics included
- Investors should review the referenced exhibit for substantive financial information
Item 8.01 · Other Events
- Updated corporate presentation for healthcare conferences, analysts, stockholders, and other audiences
- Exhibit 99.2 contains the investor-facing presentation and may outline current strategy, pipeline, or business priorities
Item EX-99.1 · Exhibit EX-99.2
- Q2 2026 product sales reached $170.4M, up 31% sequentially, confirming rapid YUTREPIA commercial adoption
- Net income $74.7M and adjusted EBITDA $96.3M marked the fourth consecutive quarter of improving profitability
- Cash and equivalents rose to $284.2M from $190.7M at December 31, 2025, strengthening funding for commercialization and clinical development
- YUTREPIA generated approximately 5,900 prescriptions and treated more than 5,000 patients since June 2025
- L606 Re-Spire pivotal study enrollment and 10 clinical studies expand potential indications, but ongoing United Therapeutics litigation remains a commercialization risk
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Liquidia Corp 8-K filings
Get the next LQDA 8-K as it lands
Follow LQDA for push alerts, or ask the research agent what this filing means.